Clinical features and outcomes in kidney transplant recipients with renal cell carcinoma: a single-center study
Kidney Research and Clinical Practice
;
: 517-524, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-786194
ABSTRACT
BACKGROUND:
Previous studies have recommended a 2- to 5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell carcinoma (RCC) and no delay for incidental early-stage RCC. Data on Asian KT recipients are unavailable.METHODS:
This is a Korean single-center retrospective study on 35 KT recipients with ESRD and RCC. Patients were classified into two groups early KT (KT performed within 1 year after nephrectomy for RCC, including KT with simultaneous nephrectomy) and delayed KT (KT performed over than 1 year after nephrectomy for RCC). Patient survival, graft survival, and cancer recurrence were compared between both groups.RESULTS:
There were no statistically significant differences in patient survival (P = 0.388), graft survival (P = 0.317), or graft rejection rate (P = 0.207) between the early and delayed KT groups. Additionally, there were no differences in pathological characteristics or RCC stage other than cancer histology acquired cystic disease-associated RCC (47.4%) was the most common RCC type in the early KT group, whereas clear cell type (62.5%) was the most common RCC type in the delayed KT group. No RCC recurrence was observed.CONCLUSION:
Patients with early-stage and asymptomatic RCC do not require a mandatory observational period prior to KT after curative nephrectomy
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Recidiva
/
Carcinoma de Células Renais
/
Estudos Retrospectivos
/
Transplante de Rim
/
Povo Asiático
/
Transplantados
/
Rejeição de Enxerto
/
Sobrevivência de Enxerto
/
Rim
/
Falência Renal Crônica
Tipo de estudo:
Estudo observacional
Limite:
Humanos
Idioma:
Inglês
Revista:
Kidney Research and Clinical Practice
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS